Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus

Pharmacotherapy

Volumn 25, Issue 2, 2005, Pages 253-264

  Grim, Shellee A ^a   Rapp, Robert P ^b   Martin, Craig A ^b   Evans, Martin E ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Methicillin resistance; Methicillin resistant Staphylococcus aureus; MRSA; TMP SMX; Trimethoprim sulfamethoxazole

Indexed keywords

ACECAINIDE; ANTIINFECTIVE AGENT; CEFALOTIN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; DIGOXIN; DRUG METABOLITE; ERYTHROMYCIN; FUSIDIC ACID; LINCOMYCIN; LINEZOLID; METHOTREXATE; METICILLIN; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PENICILLIN G; PHENYTOIN; PROCAINAMIDE; QUINOLINE DERIVATIVE; RIFAMPICIN; SULFAMETHOXAZOLE; SULFONAMIDE; TETRACYCLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMETHOPRIM; VANCOMYCIN; WARFARIN;

AGRANULOCYTOSIS; ANEMIA; ANOREXIA; ASEPTIC MENINGITIS; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BRONCHIECTASIS; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SENSITIVITY; FEVER; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOGLYCEMIA; MEDLINE; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OSTEOMYELITIS; PANCREATITIS; PENICILLIN RESISTANCE; PNEUMOCYSTIS; PNEUMONIA; RASH; REVIEW; RHABDOMYOLYSIS; SEPSIS; STEVENS JOHNSON SYNDROME; TABLET; THROMBOCYTOPENIA; VOMITING;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; HALF-LIFE; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TISSUE DISTRIBUTION; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 13544252542     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.2.253.56956     Document Type: Review

References (95)

1. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998;26(5):1179-81.
2. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-32.
3. Jevons MP. "Celbenin" resistant Staphylococci. Br Med J 1961;1:124-5.
4. Wenzel RP. The emergence of methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982;97:440-2.
5. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29(2):239-44.
6. Fritsche TR, Stephens JS, Jones RN. Changing patterns of bacterial pathogens and their antimicrobial susceptibility profiles in patients hospitalized with pneumonia: report from the SENTRY antimicrobial surveillance program, 2002 [abstr]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:C2-191.
7. Chambers HF. Community-acquired MRSA in the United States. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy [abstr]. Washington, DC: American Society for Microbiology, 2003:515.
8. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus infections caused by clonally-linked community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003;37:1050-8.
9. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002;162:2229-35.
10. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus. JAMA 1999;282:1745-51.
11. Rubin R, Harrington C, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emer Infect Dis 1999;5:9-18.
12. Welch KE, Goff DA, Fish DN, Sierawski SJ, Paladino JA. A multicenter economic analysis of bacteremia caused by methicillin-resistant Staphylococcus aureus [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1999:1865.
13. Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis 2003;37:1453-60.
14. Selvy LA, Whitby M, Johnson B. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia: is it any worse than nosocomial methicillin-sensitive Staphylococcus aureus bacteremia? Infect Control Hosp Epidemiol 2000;21:645-8.
15. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
16. Capitano B, Leshem OA, Nightingale CH, Nicolau DP. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. Am Geriatr Soc 2003;51:10-16.
17. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36: 1418-23.
18. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morbid Mortal Wkly Rep 2002;51:565-7.
19. Centers for Disease Control and Prevention. Public health dispatch: vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morbid Mortal Wkly Rep 2002;51:902.
20. Centers for Disease Control and Prevention. Brief report: vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morbid Mortal Wkly Rep 2004;53(15):322-3.
21. Cafferkey MT, Hone R, Keane CT. Antimicrobial chemotherapy of septicemia due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985;28(6):819-23.
22. Pharmacia & Upjohn Company. Zyvox (linezolid) package insert. Kalamazoo, MI: 2003.
23. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann Pharmacother 2003;37:769-74.
24. Machado ARL, Andrade SS, Barth AL, Lutz L, Sader HS, Gales AC. The emergence of linezolid-resistance among Staphylococcus aureus from cystic fibrosis patients [abstr]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:C2-1825.
25. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90.
26. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97.
27. Monarch Pharmaceuticals, Inc. Synercid (quinupristin-dalfopristin) package insert. Bristol, TN; 2003.
28. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999;44(suppl A):37-46.
29. Cubist Pharmaceuticals, Inc. Cubist (daptomycin) package insert. Lexington, MA; 2003.
30. Johnson JR. Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infections [letter]. Clin Infect Dis 2003;36:236-7.
31. Carithers HA. The first use of an antibiotic in America. Am J Dis Child 1974;128:207-11.
32. Galdston I. Behind the sulfa drugs: a short history of chemotherapy. New York: Appleton-Century-Crofts, Inc, 1943:VIII-IX.
33. Bushby SRM, Hitchings GH. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol Chemother 1968;33:72-90.
34. Zinner SH, Mayer KH. Sulfonamides and trimethoprim. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 2000. New York: Churchill Livingstone, 2000:394-404.
35. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:1098-107.
36. Centers for Disease Control and Prevention. USPHS/IDSA/ASBMT guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, 2000. MMWR Morbid Mortal Wkly Rep 2000;51(RR10):1-125.
37. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons, 2002. MMWR Morbid Mortal Wkly Rep 2002;51(RR08):1-46.
38. Penzak SR, Abate BJ. Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen. Pharmacotherapy 1997;17(2):293-301.
39. Rammelkamp CH, Maxon T. Resistance of Staphylococcus aureus to the action of penicillin. Proc Royal Soc Exper Biol Med 1942;51:386-9.
40. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003;11(9):1265-73.
41. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002;56:657-75.
42. Lyon BR, Skurry R. Antimicrobial resistance of Staphylococcus aureus: genetic basis. Microbiol Rev 1987;51(1):88-134.
43. Dale GE, Broger C, D'Arcy A, et al. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. J Mol Biol 1997;266:23-30.
44. Fung-Tomc J, Huczko E, Gradelski E, Denbleyker K, Bonner DP, Kessler RE. Emergence of homogeneously methicillin-resistant Staphylococcus aureus. J Clin Micro 1991;29(12):2880-3.
45. Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999;18(11):993-1000.
46. Hershow RC, Khayr WF, Schreckenberger PC. Ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: associated factors and resistance to other antibiotics. Am J Ther 1998;5:213-20.
47. Martin JN, Rose DA, Hadley WK, Perdreau-Remington F, Lam PK, Gerberding JL. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J Infect Dis 1999;180:1809-18.
48. Sattler CA, Mason EO, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis 2002;21:910-16.
49. Aldridge KE, Gelfand MS, Schiro DD, Barg NL. The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. Diagn Microbiol Infect Dis 1992;15:601-8.
50. Goetz MB, Mulligan ME, Kwok R, O'Brien H, Caballes C, Garcia JP. Management and epidemiologic analyses of an outbreak due to methicillin- resistant Staphylococcus aureus. Am J Medicine 1992;92:607-14.
51. Fergie JE, Purcell K. Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr Infect Dis 2001;20(9):860-3.
52. Corso A, Santos Sanches I, Aires de Sousa M, Rossi A, De Lencastre H. Spread of a methicillin-resistant and multi-resistant epidemic clone of Staphylococcus aureus in Argentina. Microb Drug Resist 1998;4(4):277-88.
53. Orrett FA. Methicillin resistance among Trinidadian isolates of community and hospital strains of Staphylococcus aureus and their patterns of resistance to non-β-lactam antibiotics. Jpn J Infect Dis 1999;52:238-41.
54. Wongwanich S, Tishyadhigama P, Paisomboon S, Ohta T, Hayashi H. Epidemiological analysis of methicillin resistant Staphylococcus aureus in Thailand. Southeast Asian J Trop Med Public Health 2000;31(1):72-6.
55. Norazah A, Liew SM, Kamel AG, Koh YT, Lim VK. DNA fingerprinting of methicillin-resistant Staphylococcus aureus by pulsed-field gel electrophoresis (PFGE): comparison of strains from 2 Malaysian hospitals. Singapore Med J 2001;42(1):15-19.
56. McDonald LC, Lauderdale TL, Lo HJ, Tsai JJ, Hung CC. Colonization of HIV-infected outpatients in Taiwan with methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Int J STD AIDS 2003;14:473-7.
57. Bishara J, Pitlik S, Samra Z, Levy I, Paul M, Leibovici L. Cotrimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997. Emerg Infect Dis 2003;9(9):1168-9.
58. Samra Z, Gadba R. Antibiotic susceptibility and phage typing of methicillin-resistant Staphylococcus aureus clinical isolates from blood cultures of 692 patients in 15 Israeli hospitals. Eur J Epidemiol 1993;9(5):559-62.
59. Verma S, Joshi S, Chitnis V, Hemwani N, Chitnis D. Growing problem of methicillin resistant Staphylococci - Indian scenario. Indian J Med Sci 2000;54(12):535-40.
60. Alonso R, Padilla B, Sanchez-Carrillo C, Munoz P, Rodriguez-Creixems M, Bouza E. Outbreak among HIV-infected patients of Staphylococcus aureus resistant to cotrimoxazole and methicillin. Infect Control Hosp Epidemiol 1997;18:617-21.
61. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994;13(1):50-5.
62. Amorim ML, Aires de Sousa M, Santos Sanches I, et al. Clonal and antibiotic resistance profiles of methicillin-resistant Staphylococcus aureus (MRSA) from a Portuguese hospital over time. Microb Drug Resist 2002;8(4):301-9.
63. Ferrara A, Morosini M, Dos Santos C, Fietta A. A survey of antimicrobial drug resistance in respiratory tract pathogens, isolated in a northern Italian teaching hospital between 1990 and 1999. J Chemother 2002;14(6):568-73.
64. Durmaz B, Durmaz R, Slain K. Methicillin-resistance among Turkish isolates of Staphylococcus aureus strains from nosocomial and community infections and their resistance patterns using various antimicrobial agents. J Hosp Infect 1997;37:325-9.
65. Okesola AO, Oni AA, Bakare RA. Nosocomial infections: methicillin resistant Staphylococcus aureus in wound infection in Ibadan, Nigeria. Afr J Med Sci 1999;28(1-2):55-7.
66. Roberts RB, Tennenberg AM, Eisner W, et al. Outbreak in a New York City teaching hospital burn center caused by the Iberian epidemic clone of MRSA. Microb Drug Resist 1998;4(3):175-83.
67. Von Eiff C, Lubritz G, Heese C, Peters G, Becker K. Effect of trimethoprim-sulfamethoxazole prophylaxis in AIDS patients on the formation of the small colony variant phenotypes of Staphylococcus aureus. Diagn Microbiol Infect Dis 2004;48:191-4.
68. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003;37:1050-8.
69. Walsh TJ, Standiford HC, Reboli AC, et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 1993;37(6):1334-42.
70. Parras F, Guerrero MC, Bouza E, et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995;39(1):175-9.
71. Preheim LC, Rimland D, Bittner MJ. Methicillin-resistant Staphylococcus aureus in Veterans Administration medical centers. Infect Control 1987;8(5):191-4.
72. Roccaforte JS, Bittner MJ, Stumpf CA, Preheim LC. Attempts to eradicate methicillin-resistant Staphylococcus aureus colonization with the use of trimethoprim-sulfamethoxazole, rifampin, and bacitracin. Am J Infect Control 1988;16(4): 141-6.
73. Kimura A, Mochaizuki T, Nishizawa K, Mashiko K, Yamamoto Y, Otsuka T. Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistani Staphylococcus aureus pneumonia in severely burned patients. J Trauma 1998;45(2):383-7.
74. Honda T, Hayasaka M, Hachiya T, Kubo K, Katsuyama T, Nagata A. Two cases of severe bronchiectasis successfully treated with a prolonged course of trimethoprim/sulfamethoxazole. Int Med 1996;35:979-83.
75. Tamer MA, Bray JD. Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis. Clin Fed 1982;21(2):125-6.
76. Bengtsson E, Svanbom M, Tunevall G. Trimethoprim-sulphamethoxazole treatment in staphylococcal endocarditis and gram-negative septicemia. Scand J Infect Dis 1974;6:177-82.
77. Emmerson AM, Garau J. Postoperative complications due to methicillin-resistant Staphylococcus aureus (MRSA) in an elderly patient: management and control of MRSA. J Hosp Infect 1992;22(suppl A):43-50.
78. Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 1998;22:873-80.
79. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998;42(12):3086-91.
80. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390-8.
81. Kaplan SA, Weinfeld RE, Abruzzo CW, McFaden K, Jack ML, Weissman L. Pharmacokinetic profile of trimethoprim-sulfamethoxazole in man. J Infect Dis 1973;128:S547-55.
82. McEvoy GK, ed. Sulfonamides. In: AHFS drug information 2004. Bethesda, MD: American Society of Health-System Pharmacists, 2004:417-32.
83. Close SJ, McBurney CR, Garvin CG, Chen DC, Martin SJ. Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus. Pharmacotherapy 2002;22(8):983-9.
84. Bushby SRM. Trimethoprim-sulfamethoxazole: in vitro microbiological aspects. J Infect Dis 1973;128:S442-62.
85. Elwell LP, Wilson HR, Knick VB, Keith BR. In vitro and in vivo efficacy of the combination of trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1986;29(6):1092-4.
86. Goldstein BP, Ripamonti IF, Bolzoni G, Carniti G, Arioli V. Rifampin plus trimethoprim: bactericidal activity and suppression of resistance in human urine in vitro. Antimicrob Agents Chemother 1979;16(6):736-42.
87. Bushby SRM, Barnett M. Trimethoprim-sulphamethoxazole tetracycline and the penicillins in vitro. Presented at the sixth International Congress of Chemotherapy, Tokyo, Japan, August 10-15, 1969.
88. Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim- sulfamethoxazole revisited. Arch Intern Med 2003;163:402-10.
89. Dailey CF, Dileto-Fang CL, Buchanan LV, et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001;45(8):2304-8.
90. Ravindran V, John J, Kaye GC, Meigh RE. Successful use of oral linezolid as a single agent in endocarditis unresponsive to conventional antibiotic therapy. J Infect 2003;47(2):164-6.
91. Howden BP, Ward BP, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38(4):521-8.
92. Bassetti M, Di Biagio A, Del Bono V, Cenderello G, Bassetti D. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Int J Antimicrob Agents 2004;24(1):83-4.
93. Mansour EHB, Jacob E, Monchi M, et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 2003;22:372-3.
94. Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002;35(8):1018-20.
95. Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(9):3002-4.